Aardvark Therapeutics, Inc.
AARD
$11.81
-$0.14-1.17%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 03/31/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 2.72M | 1.39M | 1.03M | 964.00K | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 10.47M | 9.45M | 5.09M | 2.17M | |
| Operating Income | -10.47M | -9.45M | -5.09M | -2.17M | |
| Income Before Tax | -9.31M | -8.78M | -4.18M | -2.18M | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -9.31M | -8.78M | -4.18M | -2.18M | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -9.31M | -8.78M | -4.18M | -2.18M | |
| EBIT | -10.47M | -9.45M | -5.09M | -2.17M | |
| EBITDA | -10.47M | -9.44M | -5.09M | -2.17M | |
| EPS Basic | -0.71 | -2.16 | -1.05 | -0.55 | |
| Normalized Basic EPS | -0.44 | -1.34 | -0.64 | -0.33 | |
| EPS Diluted | -0.71 | -2.16 | -1.05 | -0.55 | |
| Normalized Diluted EPS | -0.44 | -1.34 | -0.64 | -0.33 | |
| Average Basic Shares Outstanding | 13.19M | 4.06M | 3.99M | 3.97M | |
| Average Diluted Shares Outstanding | 13.19M | 4.06M | 3.99M | 3.97M | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |